Price Alert

Gilead Sciences Inc. (GILD)

NASDAQ: GILD · Real-Time Price · USD

115.34

-0.80 (-0.69%)

At close: Aug 22, 2025, 12:35 PM

-0.69% (1D)

Bid	115.33
Market Cap	143.12B
Revenue (ttm)	28.86B
Net Income (ttm)	6.31B
EPS (ttm)	7.74
PE Ratio (ttm)	14.9
Forward PE	13.77
Analyst	Buy

Ask	115.36
Volume	1,540,793
Avg. Volume (20D)	7,184,956
Open	116.90
Previous Close	116.14
Day's Range	115.23 - 118.13
52-Week Range	75.91 - 121.83
Beta	0.35

About GILD

undefined

[Read more]

Industry n/a

Sector n/a

IPO Date n/a

Employees NaN

Stock Exchange n/a

Ticker Symbol GILD

Website n/a

Full Company Profile

Analyst Forecast

According to 0 analyst ratings, the average rating for GILD stock is "n/a." The 12-month stock price forecast is $n/a, which is a decrease of 0% from the latest price.

Stock Forecasts

Next Earnings Release

Gilead Sciences Inc. is scheduled to release its earnings on Nov 5, 2025, during market hours.
Analysts project revenue of ... Unlock content with Pro Subscription

Why Price Moved

2 weeks ago

+8.28%

Gilead Sciences shares are trading higher after th... Unlock content with Pro Subscription

4 weeks ago

+2.65%

Gilead Sciences shares are trading higher after Needham upgraded the stock from Hold to Buy and announced a price target of $133.

News

20 hours ago · reuters.com

Gilead unit to acquire cell therapy developer Interius for $350 million

Gilead Sciences' unit Kite Pharma said on Thursday it will acquire privately-held biotech firm Interius BioTherapeutics for $350 million in cash to advance CAR T-cell cancer therapies that are deliver...

21 hours ago · benzinga.com

CVS Health Declines To Add Gilead's Steeply Priced New HIV Prevention Drug To Its Plans

CVS Health Inc. CVS said it will not add Gilead Sciences Inc.'s GILD new HIV prevention drug Yeztugo to its commercial plans.

1 day ago · seekingalpha.com

From Stagnation To Surge: Gilead Sciences Is Entering Its Next Growth Wave

Gilead Sciences remains a long-term Buy due to solid quarterly results, raised guidance, and continued strength in its HIV portfolio, especially Biktarvy. The recent launch of Yeztugo and a robust HIV...

2 days ago · reuters.com

Exclusive: CVS holds off adding Gilead's new HIV prevention shot to drug coverage lists

CVS Health , which runs the largest U.S. pharmacy benefit manager, will not add Gilead Sciences' new HIV prevention drug to its commercial plans for now, a spokesperson told Reuters, despite the medic...

2 days ago · businesswire.com

Gilead Sciences to Present at Upcoming Investor Conferences

FOSTER CITY, Calif.--(BUSINESS WIRE)-- #Earnings--Gilead Sciences, Inc. (Nasdaq: GILD) announced today that its executives will be speaking at the following investor conferences: Cantor Global Healthc...

3 days ago · zacks.com

GILD Stock Up 7% Post Q2 Earnings: Should You Buy Now or Wait?

Gilead's Q2 earnings beat and raised 2025 outlook lift shares 7.3%, fueled by HIV gains, Trodelvy strength, and new PrEP launch Yeztugo.

5 days ago · seekingalpha.com

Our Top 10 High Growth Dividend Stocks - August 2025

The article provides a methodology for selecting high-growth dividend-paying stocks, focusing on dividend growth and sustainability rather than high current yield. We use our proprietary models to rat...

6 days ago · zacks.com

Zacks.com users have recently been watching Gilead (GILD) quite a bit. Thus, it is worth knowing the facts that could determine the stock's prospects.

1 week ago · benzinga.com

Gilead Sciences Lifts Annual Outlook As Yeztugo Launch Nears

Gilead Sciences GILD announced its second-quarter 2025 earnings and revised annual outlook after the market closed on Thursday.

1 week ago · zacks.com

GILD Stock Rises on Q2 Earnings and Sales Beat, '25 View Up

GILD tops Q2 earnings, raises 2025 guidance as HIV drugs Biktarvy and Descovy drive revenue growth.

Load More News